Professional welcomes new clinical director partner to expand access to specialized hand therapy care.

MELVILLE, N.Y., Sept. 3, 2024 /PRNewswire-PRWeb/ — Professional Physical Therapy, a leading provider of outpatient physical therapy and rehabilitation services throughout New York, New Jersey, Connecticut, Massachusetts, and New Hampshire, announces the opening of a new hand therapy clinic in Saddle Brook NJ. This is the second clinic in the area, expanding access to specialized care.

The hand therapy clinic is conveniently located at 299 Market Street, just a short distance from the full-service Professional PT clinic in Saddle Brook. This opening is part of Professional’s strategic partnership program, which offers a unique affiliation solution for clinicians and leaders invested in ownership and operations. With this new location, even more patients in New Jersey will benefit from the clinical expertise and advanced therapeutics offered by Professional.

Eileen Purcell, OTR/L, CHT, the new Clinical Director Partner and Occupational Therapist, is enthusiastic about providing top-quality Hand Therapy services to the Saddle Brook community. Eileen states, “I am thrilled to partner with Professional Physical Therapy. It has been a great experience over the past four years to be part of a company that truly values education, patient outcomes, and creating a positive work environment with amazing colleagues. I am excited to bring hand therapy to Saddle Brook and dive into the vibrant culture.”

Eileen completed her master’s degree in occupational therapy at Wesley College. She has extensive experience working with patients of all ages. Her specialty services include Functional Capacity Evaluation (FCE), return to work rehabilitation, custom splinting, and expert care for conditions related to the elbow, shoulder, and wrist.

Additionally, the Saddle Brook HT clinic:

• Accepts most major insurance plans.
• Accepts same day referrals.
• Offers convenient hours, including early mornings and late evenings.
• Takes custom hand splinting walk-ins.
• Schedules each initial evaluation quickly, walk-in evaluations welcome.
• Provides ongoing patient education on diagnosis, treatment plans and prescribed home-exercise programs.

Professional Physical Therapy currently operates widely across five of the Northeast states. For more information and a list of all Professional Physical Therapy locations and hand therapy services, please visit http://www.professionalpt.com

About Professional Physical Therapy.
Professional Physical Therapy was founded in 1999 and is an industry leader, providing private outpatient physical and hand therapy services throughout the Northeast. Our clinical team is comprised of multi-specialty Physical, Hand and Occupational Therapists who can treat a wide variety of orthopedic injuries and conditions with excellence. Today, Professional has grown to include over 200 facilities in New York, New Jersey, Connecticut, Massachusetts, and New Hampshire.

Media Contact

Professional Physical Therapy, Professional Physical Therapy, 516-321-2400, [email protected], https://www.professionalpt.com/ 

SOURCE Professional Physical Therapy

PharmaIN Corporation has published promising research in Science Translational Medicine on their novel therapy, dCNP, which shows encouraging preclinical results against challenging cancers like colon and pancreatic adenocarcinomas. By normalizing tumor blood vessels, dCNP improves therapy resistance and boosts the immune response. As PharmaIN prepares for clinical trials, they welcome collaborators to bring this potentially life-changing therapy to patients.

BOTHELL, Wash., Sept. 3, 2024 /PRNewswire-PRWeb/ — PharmaIN Corporation, a clinical-stage biopharmaceutical company, is pleased to announce the publication of research in Science Translational Medicine detailing the mechanism and preclinical efficacy of their modified C-type natriuretic peptide (dCNP) in several solid tumor animal models, including challenging cancers like colon and pancreatic adenocarcinomas. This study, in collaboration with experts from the University of Pennsylvania, Kyushu University, Higashiosaka City Medical Center, and Case Western Reserve University School of Medicine, introduces a novel approach to improving cancer therapy.

The research addresses the tumor microenvironment (TME), where dysfunctional blood vessels contribute to therapy resistance. PharmaIN’s dCNP offers a solution by normalizing these blood vessels, reducing hypoxia, and reinvigorating anti-tumor immunity.

Professor Fuchs, MD, PhD, lead corresponding author, highlights key benefits of dCNP:

“The development of PharmaIN derivatives of CNP represents a pivotal paradigmatic shift in our quest to target the immune-suppressive tumor microenvironment and to revolutionize the anti-cancer therapeutic regimens for at least three independent reasons:

• First, using the agonist-based approach enables us to avoid the pro-angiogenic redundancy and resistance issues that undermine the efficacy of inhibitors of the VEGF pathway.
• Second, the potent anti-fibrotic and modest vasodilating activities of dCNP spare us from the necessity to intermix additional agents with dubious specificity.
• Third, and perhaps most importantly, instead of inhibiting VEGF to slow down pathologic, leaky, and dilapidated tumor angiogenesis, dCNP promotes the formation of healthy and highly functional blood vessels that efficiently restore tissue perfusion, eliminate hypoxia, and facilitate the delivery of nutrients and removal of toxic waste metabolites. The resulting reactivation of the anti-tumor immune responses is a solid foundation for including CNP-based agents into numerous anti-cancer regimens, including chemo-, radio- and immunotherapies.

However, it’s important to note that these promising results need to be confirmed in clinical trials to fully establish the efficacy and safety of dCNP in human patients.”

Dr. Elijah Bolotin, President and CEO of PharmaIN, adds:

“We are in the final stages of preclinical development and are eager to move forward towards clinical trials. While we recognize the challenges ahead, we are committed to rigorously testing this therapy to ensure its safety and effectiveness. We welcome collaborators to advance this potentially life-changing therapy to patients.”

The full research paper is available in the August 21, 2024, issue of Science Translational Medicine and can be accessed through the journal’s website or via https://pharmain.com/for-partners/.

About PharmaIN:

PharmaIN Corporation, based in Bothell, WA, specializes in advancing First- and Best-in-Class peptide therapies for self-administration through its expertise in target-specific biology and peptide drug design. By enhancing key properties like agonism, stability, and pharmacokinetics, PharmaIN develops safer, more effective drugs. With a low-risk approach, PharmaIN streamlines design and manufacturing processes, minimizes costs, and accelerates time to market. Visit our website at www.pharmain.com!

Media Contact

Akiko Nishimoto-Ashfield, PharmaIN Corp., 1 2065681450 *103, [email protected], www.pharmain.com

SOURCE PharmaIN Corp.

Nonprofit organization Team PHenomenal Hope is officially categorized as a North American patient advocacy association by the World Symposium on Pulmonary Hypertension, a leading organization in the study of rare disease pulmonary hypertension.

CHICAGO, Sept. 3, 2024 /PRNewswire-PRWeb/ — Team PHenomenal Hope, a pioneering organization dedicated to raising awareness and funds for pulmonary hypertension (PH), has been officially recognized as a patient association at the 7th World Symposium on Pulmonary Hypertension. This prestigious recognition marks a significant milestone in the organization’s journey and highlights its impact on the global PH community.

As Team PHenomenal Hope continues its mission to support patients, fund research, and raise awareness, this recognition at the 7th World Symposium on Pulmonary Hypertension serves as a testament to the organization’s enduring impact and commitment to the PH community.

Dr. Harrison “Hap” Farber, Board Chair of Team PHenomenal Hope and a leading expert in pulmonary hypertension from Tufts University, expressed his gratitude for this acknowledgment, stating, “Recognition on a global scale is truly gratifying. It reflects the dedication of everyone involved in Team PHenomenal Hope and underscores the importance of our mission to support patients and advance the understanding of this challenging disease.”

Founded 12 years ago, Team PHenomenal Hope has grown from a grassroots movement into a dynamic organization with a broad range of patient-centered programs. Dr. Patricia George, co-founder of Team PHenomenal Hope and Director of the Pulmonary Hypertension Program at National Jewish Health, reflected on the organization’s evolution, saying, “Seeing this organization grow over the past 12 years from an idea and a movement that inspired the pulmonary hypertension community into a full-fledged organization with a palette of novel, patient-centered programs is one of the most gratifying feelings I think I have felt in my life.”

Leslie Orlovsky, Executive Director of Team PHenomenal Hope, emphasized the significance of the organization’s work for the community, stating, “What we do at Team PHenomenal Hope goes beyond raising awareness. We are building a community, providing support, and giving hope to patients and families affected by pulmonary hypertension. This recognition is a testament to the strength and resilience of our community, and it motivates us to continue our mission with even greater passion.”

Team PHenomenal Hope is a nonprofit organization dedicated to raising awareness of pulmonary hypertension, a rare and life-threatening disease, and providing programs and resources to PH patients. Information about Team PHenomenal Hope and its initiatives can be found at teamph.org.

Media Contact

Katie Werner, Team PHenomenal Hope, 1 877-646-4673 102, [email protected], teamph.org

SOURCE Team PHenomenal Hope